BIMZELX® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy). View press release

View press release

Introducing

BIMZELX®(bimekizumab-bkzx)

A first-of-its-kind treatment now approved for adults with moderate to severe plaque psoriasis*

See why

*BIMZELX is the only FDA-approved biologic that selectively inhibits the 2 immune system proteins IL-17A & IL-17F (interleukins), key drivers of inflammation.

.
.

How Bimzelx
may help

In combined clinical trials†:

Most people saw
90% skin clearance

In 16 weeks, nearly 9 out of 10 people saw 90% clear skin, and were rated clear or almost clear.‡

‡88% of BIMZELX patients saw 90% skin clearance, and were rated clear or almost clear, at 16 weeks vs 3% of placebo patients.

The majority of people saw
100% clear skin

In 16 weeks, more than 6 out of 10 people saw 100% clear skin.§

§63% of BIMZELX patients saw 100% skin clearance at 16 weeks vs 1% of placebo patients.

†Results above are from the 320 mg dose of BIMZELX, given as 2 separate injections under the skin of 160 mg each every 4 weeks for the first 16 weeks followed by every 8 weeks thereafter. Results may vary. Every person responds to treatment differently.

See results

A uniquely personal approach to resources and support

BIMZELX® Copay option

From the first dose,
eligible commercially insured patients pay $15 or less‖

BIMZELX® Nurse Navigator

A Nurse Navigator dedicated
to you from day one

BIMZELX® support

Medication shipment and
insurance status tracking

Get to know BIMZELX NAVIGATE™

‖For eligible commercially insured patients only. Eligible patients who have a delay or denial of coverage may pay as little as $15 per dose of BIMZELX® for up to two years or until the patient’s commercial insurance plan approves coverage, whichever comes first. Please see full eligibility and terms.

Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.

Stay in the know
about bimzelx

Sign up for updates

BIMZELX Bridge: Eligible patients must be 18 years of age or older with commercial insurance and a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Eligible patients may pay as little as $15 per dose of BIMZELX for up to two years or until the patient’s commercial insurance plan approves coverage for the drug, whichever comes first. Program is not available (1) to patients whose prescriptions are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded health care programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s insurance covers the drug, (3) to uninsured or cash-paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. Patients may be asked to re-verify insurance coverage status during participation in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. The patient, or healthcare provider on the patient’s behalf, must not submit any claim for reimbursement for product provided under this program to any third-party payer. UCB reserves the right to end or amend this program without notice.
For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for BIMZELX by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer.

 

BIMZELX Savings: Eligible patients may pay $5 per dose. Available to individuals 18 years of age or older with commercial insurance coverage with a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. The value of the program is exclusively for the benefit of patients and is intended to be credited in full towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance and deductibles. Patient may not seek reimbursement for the value of this program from other parties, including third-party payers (ie, any health insurance program or plan, or public payers like Medicare, Medicaid, Medigap, TRICARE, VA, and DoD). Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the program. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. UCB reserves the right to amend or end this program at any time without notice.

icons/feathericon/arrow-up-circle

IMPORTANT SAFETY INFORMATION:
What is the most important information I should know about BIMZELX® (bimekizumab-bkzx)?
BIMZELX is a medicine that affects your immune system. BIMZELX may increase your risk of having serious side effects, including:

Indication: BIMZELX® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BIMZELX® (bimekizumab-bkzx)?

BIMZELX is a medicine that affects your immune system. BIMZELX may increase your risk of having serious side effects, including:

  • Suicidal thoughts and behavior have happened in some people treated with BIMZELX. Get medical help right away or call the National Suicide and Crisis Lifeline at 988 if you, your caregiver or your family member notice in you any of the following symptoms:
    • new or worsening depression or anxiety
    • thoughts of suicide, dying, or hurting yourself
    • changes in behavior or mood
    • acting on dangerous impulses
    • attempt to commit suicide
  • Infections. BIMZELX is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections.
    • Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with BIMZELX.
    • If your healthcare provider feels you are at risk for TB, you may be treated with medicine for TB before you begin treatment with BIMZELX and during your treatment.
    • Your doctor should watch you closely for signs and symptoms of TB during and after treatment with BIMZELX. Do not take BIMZELX if you have an active TB infection.

Before starting BIMZELX, tell your healthcare provider if you:

  • are being treated for an infection
  • have an infection that does not go away or that keeps coming back
  • have TB or have been in close contact with someone with TB
  • think you have an infection or have symptoms of an infection such as:
    • fever, sweats, or chills
    • muscle aches
    • cough
    • shortness of breath
    • blood in your phlegm
    • weight loss
    • warm, red, or painful skin or sores on your body different from your psoriasis
    • diarrhea or stomach pain
    • burning when you urinate or urinating more often than normal

After starting BIMZELX, call your healthcare provider right away if you have any of the signs of infection listed above. Do not use BIMZELX if you have any signs of infection unless you are instructed to by your healthcare provider. See “What are the possible side effects of BIMZELX?” for more information about side effects.

What is BIMZELX?

BIMZELX is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy).

  • It is not known if BIMZELX is safe and effective in children.

Before using BIMZELX, tell your healthcare provider about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed in the section “What is the most important information I should know about BIMZELX?”
  • have a history of depression, or suicidal thoughts or behavior
  • have liver problems
  • have inflammatory bowel disease (Crohn’s disease or ulcerative colitis)
  • have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with BIMZELX.
  • are pregnant or plan to become pregnant. It is not known if BIMZELX can harm your unborn baby.
    • If you become pregnant while taking BIMZELX, you are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-311-8972 to enroll in this registry or visit http://mothertobaby.org/pregnancy-studies/.
  • are breastfeeding or plan to breastfeed. It is not known if BIMZELX passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with BIMZELX.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

What are the possible side effects of BIMZELX?

BIMZELX may cause serious side effects. See “What is important information I should know about BIMZELX?”

  • Elevated liver enzyme levels. Your healthcare provider will do blood tests to check your liver enzyme levels before starting treatment and during treatment with BIMZELX. Your healthcare provider may temporarily stop or permanently stop your treatment with BIMZELX if you develop liver problems. Call your healthcare provider right away if you develop any signs or symptoms of liver problems, including:
    • pain on the right side of your stomach-area
    • feeling very tired
    • loss of appetite
    • nausea and vomiting
    • itching
    • dark urine
    • light-colored stool
    • yellowing of your skin or the whites of your eyes
  • Inflammatory bowel disease. New cases of inflammatory bowel disease or “flare-ups” have happened with BIMZELX. If you have inflammatory bowel disease (Crohn’s disease or ulcerative colitis), tell your healthcare provider if you have worsening disease symptoms during treatment with BIMZELX or develop new or worsening signs of Crohn’s disease or ulcerative colitis.

The most common side effects of BIMZELX include:

  • upper respiratory tract infections
  • headache
  • herpes simplex infections (cold sores in or around the mouth)
  • small red bumps on your skin
  • feeling tired
  • fungal infections (oral thrush or infections in the mouth, throat, skin, nails, feet, or genitals)
  • pain, redness, or swelling at the injection site
  • stomach flu (gastroenteritis)
  • acne

These are not all of the possible side effects of BIMZELX. Call your doctor for medical advice about side effects.

Use BIMZELX exactly as your doctor tells you to use it.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.